$211 Million is the total value of Prosight Management, LP's 41 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 72.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRTA | Buy | PROTHENA CORP PLC | $21,670,549 | +9.0% | 447,092 | +35.5% | 10.27% | -5.3% |
| GLPG | Sell | GALAPAGOS NVspon adr | $14,509,320 | -29.7% | 375,500 | -19.2% | 6.88% | -38.9% |
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $13,639,181 | +126.5% | 567,826 | +83.9% | 6.47% | +96.9% |
| HUM | Buy | HUMANA INC | $11,651,040 | +31.8% | 24,000 | +39.1% | 5.52% | +14.6% |
| CNC | New | CENTENE CORP DEL | $10,202,347 | – | 161,404 | +100.0% | 4.84% | – |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $10,016,000 | -18.9% | 3,200,000 | +82.4% | 4.75% | -29.5% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $8,962,105 | +568.8% | 1,074,593 | +820.6% | 4.25% | +481.3% |
| ALKS | Sell | ALKERMES PLC | $8,912,691 | -0.1% | 316,165 | -7.4% | 4.22% | -13.2% |
| HZNP | Sell | HORIZON THERAPEUTICS PUB L | $8,844,160 | -13.6% | 81,035 | -10.0% | 4.19% | -24.9% |
| ORIC | Buy | ORIC PHARMACEUTICALS INC | $8,806,500 | +26.7% | 1,545,000 | +30.9% | 4.18% | +10.2% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $8,097,600 | – | 80,000 | +100.0% | 3.84% | – |
| MGTX | Sell | MEIRAGTX HLDGS PLC | $7,697,701 | -27.7% | 1,488,917 | -8.9% | 3.65% | -37.2% |
| ADCT | Buy | ADC THERAPEUTICS SA | $6,351,852 | +257.0% | 3,257,360 | +603.1% | 3.01% | +210.4% |
| ARCT | New | ARCTURUS THERAPEUTICS HLDGS | $6,112,350 | – | 255,000 | +100.0% | 2.90% | – |
| STTK | Sell | SHATTUCK LABS INC | $5,943,704 | +22.3% | 2,021,668 | -4.3% | 2.82% | +6.3% |
| ABCL | Buy | ABCELLERA BIOLOGICS INC | $5,681,601 | +73.8% | 753,528 | +133.5% | 2.69% | +51.0% |
| UNH | Buy | UNITEDHEALTH GROUP INC | $5,167,772 | +94.9% | 10,935 | +118.7% | 2.45% | +69.4% |
| OPCH | Buy | OPTION CARE HEALTH INC | $4,921,173 | +5.6% | 154,900 | +0.0% | 2.33% | -8.2% |
| Sell | QUIDELORTHO CORP | $4,307,947 | +0.6% | 48,355 | -3.3% | 2.04% | -12.6% | |
| CUE | Sell | CUE BIOPHARMA INC | $4,112,122 | -21.6% | 1,151,855 | -37.4% | 1.95% | -31.9% |
| JNJ | New | JOHNSON & JOHNSON | $3,907,550 | – | 25,210 | +100.0% | 1.85% | – |
| NARI | New | INARI MED INC | $3,832,881 | – | 62,081 | +100.0% | 1.82% | – |
| ALDX | Sell | ALDEYRA THERAPEUTICS INC | $3,807,629 | -36.3% | 383,447 | -55.3% | 1.80% | -44.6% |
| PCRX | New | PACIRA BIOSCIENCES INC | $3,718,730 | – | 91,123 | +100.0% | 1.76% | – |
| LBPH | New | LONGBOARD PHARMACEUTICALS IN | $3,611,406 | – | 900,600 | +100.0% | 1.71% | – |
| New | ERASCA INC | $3,549,061 | – | 1,179,090 | +100.0% | 1.68% | – | |
| CMPX | New | COMPASS THERAPEUTICS INC | $2,218,041 | – | 678,300 | +100.0% | 1.05% | – |
| GRPH | Sell | GRAPHITE BIO INC | $2,147,832 | -29.4% | 876,666 | -4.4% | 1.02% | -38.6% |
| KALV | Sell | KALVISTA PHARMACEUTICALS INC | $1,886,400 | -55.1% | 240,000 | -61.4% | 0.89% | -61.0% |
| GALAPAGOS NVcall | $1,545,600 | -12.9% | 40,000 | 0.0% | 0.73% | -24.3% | ||
| MODV | New | MODIVCARE INC | $1,299,204 | – | 15,452 | +100.0% | 0.62% | – |
| TDOC | New | TELADOC HEALTH INC | $1,188,810 | – | 45,900 | +100.0% | 0.56% | – |
| New | KEZAR LIFE SCIENCES INCcall | $626,000 | – | 200,000 | +100.0% | 0.30% | – | |
| INSM | New | INSMED INC | $449,421 | – | 26,359 | +100.0% | 0.21% | – |
| New | 2SEVENTY BIO INC | $433,877 | – | 42,537 | +100.0% | 0.21% | – | |
| MORF | Sell | MORPHIC HLDG INC | $318,585 | -72.3% | 8,464 | -80.3% | 0.15% | -75.9% |
| AZYO | Buy | AZIYO BIOLOGICS INC | $296,629 | -62.3% | 196,443 | +6.2% | 0.14% | -67.1% |
| BBIO | Sell | BRIDGEBIO PHARMA INC | $215,540 | -68.2% | 13,000 | -85.4% | 0.10% | -72.4% |
| Buy | THE ONCOLOGY INSTITUTE INC | $191,101 | -58.0% | 281,902 | +2.3% | 0.09% | -63.3% | |
| LFST | Sell | LIFESTANCE HEALTH GROUP INC | $66,870 | -95.3% | 9,000 | -96.9% | 0.03% | -95.9% |
| XBI | New | SPDR SER TRs&p biotech | $20,805 | – | 273 | +100.0% | 0.01% | – |
| PSNL | Exit | PERSONALIS INC | $0 | – | -58,668 | -100.0% | -0.06% | – |
| Exit | TENAYA THERAPEUTICS INC | $0 | – | -107,063 | -100.0% | -0.12% | – | |
| EOLS | Exit | EVOLUS INC | $0 | – | -66,438 | -100.0% | -0.27% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -265,000 | -100.0% | -0.31% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -32,193 | -100.0% | -0.34% | – |
| BMEA | Exit | BIOMEA FUSION INC | $0 | – | -81,907 | -100.0% | -0.38% | – |
| Exit | CASSAVA SCIENCES INCput | $0 | – | -40,900 | -100.0% | -0.66% | – | |
| Exit | SEAGEN INCcall | $0 | – | -12,000 | -100.0% | -0.84% | – | |
| OSH | Exit | OAK STR HEALTH INC | $0 | – | -84,000 | -100.0% | -0.98% | – |
| CSII | Exit | CARDIOVASCULAR SYS INC DEL | $0 | – | -145,916 | -100.0% | -1.08% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -72,116 | -100.0% | -1.37% | – |
| HCAT | Exit | HEALTH CATALYST INC | $0 | – | -347,724 | -100.0% | -2.02% | – |
| TNET | Exit | TRINET GROUP INC | $0 | – | -78,000 | -100.0% | -2.88% | – |
| ALBO | Exit | ALBIREO PHARMA INC | $0 | – | -486,726 | -100.0% | -5.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.